Skip Navigation


Europace Advance Access originally published online on March 1, 2007
Europace 2007 9(4):239-245; doi:10.1093/europace/eum011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
9/4/239    most recent
eum011v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hemels, M. E.W.
Right arrow Articles by Van Gelder, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemels, M. E.W.
Right arrow Articles by Van Gelder, I. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

ANTIARRHYTHMIC DRUGS

Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function

Martin E.W. Hemels, Ans C.P. Wiesfeld, Dirk J. Van Veldhuisen, Maarten P. Van den Berg and Isabelle C. Van Gelder*

Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

Aims To compare outcome of a serial cardioversion strategy in atrial fibrillation (AF) patients with and without systolic heart failure (HF).

Methods and results In patients with new-onset persistent AF and systolic HF [left ventricular ejection fraction (LVEF) <0.40] outcome of a serial electrical cardioversion (ECV) and serial antiarrhythmic drug strategy was compared with a control group of patients without HF. Follow-up was 18 months. Sixty-four consecutive patients with systolic HF (mean age 64 ± 12 years, 50% coronary artery disease, LVEF 0.30 ± 0.07) were enrolled and compared with 48 consecutive patients without HF (mean age 66 ± 8 years, all LVEF >0.50, 40% lone AF). Success of ECV and occurrence of subacute and late recurrences in patients with and without HF were comparable. After the first relapse, AF was accepted in significantly more HF patients (23 vs. 4%, P < 0.01). Significantly less HF patients underwent serial ECV and antiarrhythmic drug approach (42 vs. 71%, respectively, P < 0.001). At the end of follow-up more HF patients were in permanent AF (45 vs. 29%, P = 0.03).

Conclusion Recurrence pattern after ECV is comparable between patients with and without systolic HF, but outcome of a serial cardioversion strategy is worse in HF patients, possibly related to a less stringent use of this approach.

Key Words: Atrial fibrillation, Heart failure, Electrical cardioversion, Antiarrhythmic drugs, Rhythm control

* Corresponding author. Tel. +31 50 3612355; fax +31 50 3614391. E-mail address: i.c.van.gelder{at}thorax.umcg.nl

Manuscript submitted 1 May 2006. Accepted after revision 10 December 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.